Report of a case with gallbladder carcinoma: P53 expression of the peritumor epithelium might predict biliary tract recurrence

Takano, Atsushi; Nakagomi, Hiroshi; Ikegame, Kou; Yamamoto, Atsushi; Watanabe, Hideki; Nakada, Haruka; Inoue, M.; Sugai, Hidemitsu; Yasutome, Michiya; Furuya, Kazushige; Hada, Masao; Miyasaka, Yoshiaki; Oyama, Toshio; Omata, Masao

doi:10.1016/j.ijscr.2016.10.042

Cited by 7 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their case study, though the remnant of the cystic duct after surgery exhibited no signs of neoplasm when analysed with H&E staining, significant p53 overexpression was observed using immunostaining. The patient suffered a recurrence in the bile duct after 2.5 years [71].…”

Section: Discussionmentioning

confidence: 96%

“…Under normal circumstances, p53 inhibits proliferation of stressed and damaged cells thereby effectively stopping tumour development [69]. Mutations of the TP53 gene is one of the common genetic abnormalities found in most human cancers [70,71]. The most common mechanism of inactivation of p53 arises from point mutation that results in a translational product that has altered conformation and defective functionality.…”

Section: Discussionmentioning

confidence: 99%

“…Nonsense mutation or methylation of the p53 gene can result in total loss of p53 protein [68]. A significant amount of TP53 mutations identified so far are missense which extends the half-life of protein by several hours causing intranuclear accumulations and the same can be observed through immunohistochemistry [6,71]. TP53 amplification and p53 accumulation could be independent events as overexpression of wild-type protein were noted in studies and this could be due to stabilisation or disruption of its proteolysis by other interacting molecules involved in GBC carcinogenesis [73].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Role of CYCLIN D1, E-Cadherin, EGFR, Her-2, KI67, and P53 Expressions as Prognostic Markers in Gall Bladder Cancer

Agarwal¹,

Bansal²,

Gupta³

2022

PJMHS

View full text Add to dashboard Cite

Introduction: Worldwide gall bladder cancer (GBC) is known to be the commonest malignant tumour of the biliary tract .It is the most aggressive carcinoma of the biliary tract with short median survival from the time of diagnosis. The aggressive biologic behavior of the carcinoma and non-availability of sensitive screening tests for early detection may be responsible for the poor prognosis associated with GBC. Owing to the delayed diagnosis at an advanced stage, only 10% of the patients are found to be eligible for a curative surgical resection. Material and Methods: All consecutive patients diagnosed with neoplastic and non-neoplastic gallbladder lesions in the Department of Pathology, Subharti Medical College were included in the study between the year 2017 -2019. The hematoxylin and Eosin stained biopsies of 320 patients were assessed and out of them 100 patients were chosen as the sample for the study. The clinicopatholgical data of the 100 patients were compiled into a data base and de-identified. Results: Age distribution of Gall Bladder lesion cases in our study was from 30 years to more than 60 years of age. 46.20% of females in the age group of 45 years to 60 years presented with mass in the gall bladder. There was significant difference in the presence of mass between the Neoplastic and non-neoplastic group among 45-60 years of age (p<0.001). It was analyzed that there had been a significant difference between the neoplastic and non neoplastic tumour morphology and age distribution among males. The neoplastic tumours were highest in >60 years age group while neoplastic tumours were highest among 45-60 years age group . The presence of E-cadherin, Ki67 and P53 together suggested the presence of histological grade of carcinoma. There was no significant association between the presence of metastasis and biomarkers concentrations.The presence of E-cadherin, Ki67 and P53 together suggested the presence clinical stage of carcinoma . Conclusions: The minimal response of advanced cases of GBC to traditional treatments calls for new prognostic and treatment perspectives to be identified. Novel prognostic biomarkers could bring about the needed breakthrough in this regard as they will help in the identification of patients who will benefit tremendously from adjuvant and targeted therapies. Keywords: Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, p53 tumor marker ,neoplastic ,non -neoplastic Gall bladder lesions

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Role of CYCLIN D1, E-Cadherin, EGFR, Her-2, KI67, and P53 Expressions as Prognostic Markers in Gall Bladder Cancer

Agarwal¹,

Bansal²,

Gupta³

2022

PJMHS

View full text Add to dashboard Cite

show abstract

“…While some studies indicate that overexpression of p53 could be an early event in the carcinogenesis of well-differentiated adenocarcinomas of the gall-bladder [13], others define p53 overexpression as a late event in the carcinogenesis process due to increased levels observed in samples from significantly progressed GBC [14,15]. p53 levels has been suggested as a means to predict recurrence of malignancy after surgical resection by immunostaining of remnant tissue sample [16]. Kaur et al, linked p53 overexpression inversely to the grade of tumour and suggested p53 might not play a role in the metastasis of GBC [17].…”

Section: P53 • 1031mentioning

confidence: 99%

Clinicopathological And Prognostic Significance Of Immuno-Expression Of Cyclin D1, E-Cadherin, EGFR, HER- 2, Ki67, And P53 In Gall Bladder Cancer And Its Precursor Lesions-A Review

Agarwal¹

2022

Journal of Pharmaceutical Negative Results

View full text Add to dashboard Cite

Gallbladder carcinoma (GBC) is an aggressive and common cancer of the biliary tract. It develops on the epithelia of the gallbladder and is has the ability to rapidly metastasize to nearby organs and distant lymph nodes. It also has the shortest median survival time when compared to other biliary tract cancers [1]. As the disease rarely presents a distinct set of clinical symptoms, delayed diagnosis contributes heavily towards the negative prognosis widely associated with the disease [2]. The molecular mechanisms and underlying changes that bring about carcinogenesis of the gallbladder epithelia, though widely studied have not been fully understood. Chronic inflammation [3], dysplasia [4] and adenoma [5] among other factors have been observed to increase the risk of developing GBC among other risk factors. With current treatment options offering only limited curative capacities, identifying and studying biomarkers with potential to speed up prognostics and having clinical applicability has become a priority. These biomarkers, apart from playing an important role in carcinogenesis, need to be specific for GBC and their levels should vary significantly enough to differentiate between malignant and benign conditions. Though several such molecules have been identified and used in diagnostic trials, the availability of disease-specific and highly sensitive markers for GBC is yet a task to be achieved. Isolation of such prognostic markers will help in understanding disease progression [6]. Further, expression levels of these prognostic markers can be used to aid in the determination of the clinical course of action, patient response to therapy and the need for adjuvant therapy [7]. An ideal prognostic marker should be easily quantifiable with high sensitivity, specificity and its levels should significantly vary to be able to differentiate benign conditions from malignancy. A clinically applicable prognostic marker should be able to predict recurrence, survivability and need for adjuvant therapies. Several categories of markers have been studied to date and include tumour markers such as CA125, CA19-9, CEA, inflammatory markers like CRP, tumour suppressors like p53, E-cadherin etc. In this review we hope to explore the future prospects of some of these markers based on available literature.

show abstract

“…While some studies indicate that overexpression of p53 could be an early event in the carcinogenesis of well-differentiated adenocarcinomas of the gall-, others define p53 overexpression as a late event in the carcinogenesis process due to increased levels observed in cases from ominously progressed GBC [10]. P53 levels has been suggested as a means to predict recurrence of malignancy after surgical resection by immunostaining of tissue sample [11]. Kaur et al, linked p53 overexpression inversely to the grade of tumour and suggested p53 might not play a role in the metastasis of GBC [12].…”

Section: P53mentioning

confidence: 99%

A Study of Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, and p53 Tumor Marker Expressions in Neoplastic and Non -neoplastic Gall Bladder Lesions and their Clinico-pathological Correlation

Agarwal

Bansal

Gupta

2022

ijmsdr

View full text Add to dashboard Cite

Background: Worldwide gall bladder cancer (GBC) is known to be the commonest malignant tumour of the biliary tract. It is the most aggressive carcinoma of the biliary tract with short median survival from the time of diagnosis. The aggressive biologic behaviour of the carcinoma and non-availability of sensitive screening tests for early detection may be responsible for the poor prognosis associated with GBC. Material and Methods: Patients diagnosed with neoplastic and non-neoplastic gallbladder lesions in the Department of Pathology, Subharti Medical College in India were included in the study. Gall bladder biopsies findings and the clinic-pathological data were compiled and different immune-markers diagnostic and therapeutic usefulness were studied . Results: 24 (24.0%) of the cases were in the age group of 51-60 Years. In 38 (38.0%) of the cases the site of lesion was Fundus. 55 (55.0%) of cases had associated stones. 36 (36.0%) of them had P53: strong over expression, 40 (40.0%) of the them had ki67: strong over expression, 25 (25.0%) had EGFR: strong over expression whereas negative expression for Her2/Neu was found in 61 (61.0%) of the cases. Cyclin D1: moderate over expression was found in 27 (27.0%) of them and moderate over expression of E-cadherin were found in 22 (23.2%) cases. Conclusions: Novel prognostic biomarkers could bring about the needed breakthrough in gall bladder cancer diagnosis and treatment. We conclude that the biomarkers studied by us may help in the identification of cases who may benefit tremendously from adjuvant and targeted therapies. Key words: Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, p53, tumour marker, neoplastic , non –neoplastic, Gall bladder lesions.

show abstract

Report of a case with gallbladder carcinoma: P53 expression of the peritumor epithelium might predict biliary tract recurrence

Cited by 7 publications

References 24 publications

Role of CYCLIN D1, E-Cadherin, EGFR, Her-2, KI67, and P53 Expressions as Prognostic Markers in Gall Bladder Cancer

Role of CYCLIN D1, E-Cadherin, EGFR, Her-2, KI67, and P53 Expressions as Prognostic Markers in Gall Bladder Cancer

Clinicopathological And Prognostic Significance Of Immuno-Expression Of Cyclin D1, E-Cadherin, EGFR, HER- 2, Ki67, And P53 In Gall Bladder Cancer And Its Precursor Lesions-A Review

A Study of Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, and p53 Tumor Marker Expressions in Neoplastic and Non -neoplastic Gall Bladder Lesions and their Clinico-pathological Correlation

Contact Info

Product

Resources

About